Research in my lab is aimed at using biochemical approaches to evaluate structure-activity relationships for diverse neurological and immunological disease targets, and use this information to drive the selection and characterization of lead molecules and ultimately the identification of development transition candidates. The success of any pharmaceutical company relies on the ability to develop successful drugs. I have been fortunate to have worked on 12 programs that were carried into clinical trials, including blockbusters AVONEX® (interferon beta-1a) and TYSABRI® (natalizumab), which are currently used for treatment of multiple sclerosis. Currently, two projects that I helped to develop are in clinical trials: anti-LINGO-1 mAb (BIIB033), which targets the repair of damaged neurons in the CNS; and neurotrophic protein Neublastin (BG00010), which is for treatment of neuropathic pain. A third project, PLEGRIDY™ (BIIB017), a long-acting pegylated version of AVONEX, has completed clinical trials and is awaiting FDA approval.

In collaboration with biologists, my lab is currently investigating the mechanism of action of LINGO-1, LINGO-1–related LRR-Ig proteins and antagonists of the pathways; studying ADME and PK/efficacy relationships of NBN and long-acting forms of NBN; performing structure-activity studies with meteorin and cometin; investigating antagonists of death receptor 6 pathway; and working on method to enhance the delivery of proteins to the brain.

Education

  • Ph.D., Cornell University, Ithaca, NY, 1983
  • B.A., Franklin and Marshall College, Lancaster, PA, 1976

Selected Publications

See more scientists